.

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

CHANTIX Drug Profile

« Back to Dashboard
Chantix is a drug marketed by Pfizer Inc and is included in one NDA. It is available from eight suppliers. There are three patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and sixty-nine patent family members in fifty-five countries.

The generic ingredient in CHANTIX is varenicline tartrate. There are six drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the varenicline tartrate profile page.

Summary for Tradename: CHANTIX

Patents:3
Applicants:1
NDAs:1
Suppliers / Packagers: see list8
Drug Prices: :see details

Pharmacology for Tradename: CHANTIX

Clinical Trials for: CHANTIX

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pfizer Inc
CHANTIX
varenicline tartrate
TABLET;ORAL021928-001May 10, 2006RXNo6,410,550May 10, 2020YY
Pfizer Inc
CHANTIX
varenicline tartrate
TABLET;ORAL021928-002May 10, 2006RXYes6,410,550May 10, 2020YY
Pfizer Inc
CHANTIX
varenicline tartrate
TABLET;ORAL021928-001May 10, 2006RXNoOct 15, 2017
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: CHANTIX

Drugname Dosage Strength RLD Submissiondate
varenicline tartrateTablets0.5 mg and 1 mgChantix5/10/2010

Non-Orange Book Patents for Tradename: CHANTIX

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,605,610 Aryl fused azapolycyclic compounds<disabled in preview>
6,951,938 Aryl fused azapolycyclic compounds<disabled in preview>
6,897,310 Aryl fused azapolycyclic compounds<disabled in preview>
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: CHANTIX

Country Document Number Estimated Expiration
Taiwan513412<disabled in preview>
Guatemala199800200A<disabled in preview>
Serbia50814<disabled in preview>
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: CHANTIX

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
442Luxembourg<disabled>91442, EXPIRES: 20210926
5Finland<disabled>
1044189/01Switzerland<disabled>PRODUCT NAME: VARENICLIN; REGISTRATION NUMBER/DATE: SWISSMEDIC 57736 21.12.2006
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc